IVF denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for IVF are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Deny IVF as "Not FDA-Approved" — and Why This Is Often Appealable

A "not-FDA-approved" denial in the context of IVF is nuanced because IVF as a procedure is not itself an FDA-approved drug or device in the traditional sense — it is a clinical practice governed by laboratory standards and professional guidelines. These denials most often arise in one of two scenarios: (1) Aetna's policy language ties coverage to FDA-approval status of a specific component of the IVF process (such as a particular laboratory technique, genetic testing protocol like PGT, or a specific device used during the cycle), or (2) the denial is actually a coverage exclusion dressed in FDA-approval language when the plan does not cover IVF at all. Identifying which scenario applies to your denial is essential before you appeal.

## Your Federal Appeal Rights

• Internal appeal: You are entitled under ERISA §503 (self-funded) or state law (fully insured) to a complete internal review. Request the exact policy language and the clinical or coverage criteria Aetna used.
• External review (ACA §2719): After exhausting internal appeals, you may seek independent external review within approximately 4 months (180 days) of the denial notice. If a component of the IVF protocol is being withheld and delay would harm your health, expedited review is available.

## The Concrete Appeal Process

1. Obtain the full denial rationale: Ask Aetna for the specific Clinical Policy Bulletin and the exact regulatory basis cited — which component, device, or technique is alleged to lack approval, and under what standard. 2. Verify FDA clearance status: For any device or laboratory technique at issue, your provider can document its current FDA clearance or 510(k) status from the FDA's public device database. 3. Distinguish regulatory from coverage: If Aetna is conflating a coverage exclusion with an FDA-approval argument, your appeal letter should clearly separate the two and address each independently. 4. Submit a Level 1 internal appeal with a prescriber letter and any FDA-clearance documentation for the disputed component. 5. Request external review if the internal appeal is upheld.

## Documentation to Gather

• FDA clearance documentation: If the denial targets a specific device or technique (e.g., a genetic screening method), obtain documentation of its regulatory status from your clinic or the device manufacturer.
• Professional society standards: A letter from your reproductive endocrinologist citing the ASRM Practice Committee's position on the technique or protocol at issue as an accepted standard of care.
• Prescriber medical-necessity letter: Explaining why the full IVF protocol as prescribed — including any disputed component — is medically necessary for your specific clinical situation.
• Plan documents: Your Summary Plan Description (SPD) and Evidence of Coverage (EOC) to confirm whether the plan excludes IVF explicitly or only conditionally.
• Infertility diagnosis records: Supporting the underlying medical necessity of proceeding with IVF.

## Criteria-Mapping Structure

Create a checklist addressing each basis for denial. For FDA-related arguments, cite the specific regulatory status documentation. For coverage arguments, cite the plan document language directly. Where Aetna's own Clinical Policy Bulletin acknowledges an ASRM-supported technique as a covered indication, highlight that language in your appeal. External reviewers look for whether Aetna applied its own stated criteria consistently.